JPM26: J&J reveals oncology strategy

GlobalData Healthcare

Tue, January 13, 2026 astatine 10:12 AM CST 4 min read

CEO Joaquin Duato presented a beardown outlook for Johnson & Johnson's (J&J) gross maturation successful 2026, with peculiar optimism astir oncology. Duato identified six large maturation drivers, 3 successful pharma (oncology, immunology, and neuroscience) and 3 successful medtech (surgery, cardiovascular, and vision). These drivers presumption J&J to scope 5-7% yearly maturation and adjacent exceeding that by the extremity of the decade, with imaginable to scope treble digit maturation successful the 2030s. Oncology is acceptable to play a large relation successful J&J’s optimistic gross outlook, generating $50bn.

The oncology portfolio volition beryllium driven by J&J’s continuing dominance successful aggregate myeloma (MM), which J&J hopes volition scope $25bn successful income successful 2030. J&J’s largest franchise, Darzalex/Faspro (daratumumab), volition marque up implicit fractional of this, arsenic it is cardinal to galore current, arsenic good arsenic pipeline MM regimens.

J&J besides expect a important summation successful income for their compartment therapy, Carvykti (ciltacabtagene autoleucel), contempt wide headwinds successful the compartment therapy market. Carvykti income are not restricted from a proviso perspective, and it is besides expected to summation a important information of precocious enactment patients. The 2 bispecific T-cell engagers (TCEs) successful J&J’s portfolio, Tecvaley (teclistamab) and Talvey (talquetamab), volition play a large relation arsenic well, bolstering income of Darzalex with caller combinations and gaining marketplace stock successful the relapsed/refractory setting. J&J’s winning strategy for MM is to ever person an enactment for a diligent to person a J&J therapy crossed each therapy lines.

Regarding the ways to support this dominance, Duato quoted 2 large platforms. The archetypal 1 is an upcoming trispecific TCE, ramantamig, which combines the targets of Tecvaley and Talvey, presently successful Phase I objective trials. The 2nd method is processing the starring successful vivo CAR-T successful MM done their concern with Kelonia Therapeutics. This collaboration, which was announced successful November 2025, followed acquisitions of successful vivo CAR-T developers by Bristol-Myers Squibb, AstraZeneca, and AbbVie and Gilead implicit 2025, but J&J has the vantage of leveraging their existent presumption successful MM.

When asked which of J&J’s franchises were being underestimated, the CEO mentioned 2 successful Oncology. Starting with the Rybrevant (amivantamab) and Lacluze (Lazertinib), these drugs person managed to show a important betterment successful wide endurance successful archetypal enactment epidermal maturation origin receptor affirmative (EGFR+) non-small compartment lung crab (NSCLC) compared to AstraZeneca’s blockbuster Tagrisso (Osimertinib) successful the MARIPOSA trial. With Rybrevant and Lacluze acceptable to displace Tagrisso successful this setting, arsenic good arsenic a subcutaneous mentation of Rybrevant becoming available, income are acceptable to summation rapidly. The CEO besides mentioned affirmative information readouts for Rybrevant successful caput and cervix and colorectal cancers. According to GlobalData’s expert statement forecast, Rybrevant and Lacluze volition scope $6.3bn successful planetary income successful 2030. J&J besides judge that Inlexzo’s forecasted income are underestimated. Inlexzo is an intravesical transportation strategy for gemcitabine, presently indicated for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder crab with carcinoma successful situ and has importantly improved connected the erstwhile modular of attraction which was surgery. J&J expects important statement expansions for Inlexzo enabling a accelerated income growth. According to GlobalData’s Analyst statement forecast, Inlexzo volition scope $3.0bn successful planetary income successful 2030.